Tuesday, September 27, 2016

Oculus Innovative Sciences Receives U.S. FDA Approval for New Post-Dermal-Procedures Product for Removal of Foreign Material Including Microorganisms

Source:  Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s new post-dermal-procedures product.

Under the supervision of a healthcare professional, the product is intended for the removal of foreign material including microogranisms and debris from post­dermal procedures.

“Within my practice I utilize the Microcyn Technology (hypochlorous acid or HOCl) post-procedure and have been most impressed with its ability to accelerate the healing process, manage post-procedure symptoms and protect against secondary infections. I find these HOCl products to be safer, non-cytotoxic and a more effective alternative to povidone-iodine and chlorhexidine. Now, with this approval from the FDA, I believe my peers will benefit from adding Microcyn-based products to their treatment protocols,” said Dr. Michael Gold, board-certified dermatologist and cosmetic surgeon, and founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, the Laser & Rejuvenation Center and Tennessee Clinical Research Center, all located in Nashville, Tennessee.

Oculus’ dermatology division, IntraDerm, will begin marketing the post­dermal-procedures product in the United States beginning in March 2017.

About IntraDerm Pharmaceuticals
A division of Oculus Innovative Sciences, IntraDerm Pharmaceuticals is a global dermatology enterprise with an initial focus on Microcyn® Technology and LipoGrid® Technologies.  The division’s headquarters are in Petaluma, California with the international sales operations in the Netherlands, and manufacturing operations in the United States and Latin America.  More information can be found at www.intraderm.com.
About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.

No comments:

Post a Comment